M&A Deal Summary

Pfizer Acquires King Pharmaceuticals

On March 1, 2011, Pfizer acquired life science company King Pharmaceuticals for 3.6B USD

Acquisition Highlights
  • This is Pfizer’s 13th transaction in the Life Science sector.
  • This is Pfizer’s 12th largest (disclosed) transaction.
  • This is Pfizer’s 13th transaction in the United States.
  • This is Pfizer’s 1st transaction in Tennessee.

M&A Deal Summary
Date 2011-03-01
Target King Pharmaceuticals
Sector Life Science
Buyer(s) Pfizer
Deal Type Add-on Acquisition
Deal Value 3.6B USD

Target

King Pharmaceuticals

Bristol, Tennessee, United States
website
King Pharmaceuticals LLC is a vertically integrated branded pharmaceutical company. King seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company's focus in specialty-driven markets, particularly neuroscience and hospital. King's wholly owned subsidiary, Alpharma, LLC, is also a leader in the development, registration, manufacture and marketing of pharmaceutical products for food producing animals.

Search 193,092 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pfizer

New York, New York, United States

website

Category Company
Founded 1849
Sector Life Science
Employees8,300
Revenue 58.5B USD (2023)
DESCRIPTION
Pfizer office in Lake Forest, Illinois.
Pfizer office in Lake Forest, Illinois.

Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.

DEAL STATS #
Overall 15 of 43
Sector (Life Science) 13 of 39
Type (Add-on Acquisition) 13 of 31
State (Tennessee) 1 of 1
Country (United States) 13 of 31
Year (2011) 2 of 5
Size (of disclosed) 12 of 21
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-02-07 Ferrosan A/S

Soeborg, Denmark

Ferrosan Consumer Health is engaged in the sale of science-based consumer healthcare products primarily in the Nordic region and the emerging markets of Russia and Central and Eastern Europe. Ferrosan Consumer Health offers a focused product portfolio of well-established brands including Multi-tabs®, the reference product in the multivitamin segment in the Nordic region, Bifiform®, a market-leading fast growing probiotics product range, Fri Flyt/Active Omega-3, a premium product range addressing the omega-3 market for heart and joint health, and IMEDEEN®, the global leader within oral skin care.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-04-04 Capsugel Belgium NV

Colmar, France

Capsugel Belgium NV is a provider of hard capsules and an innovator in drug delivery systems for the pharmaceutical, OTC and health and nutrition industries. Capsugel offers a comprehensive array of products and services, from hard gelatin, vegetarian and liquid-filled capsules, to innovative R&D equipment and liquid formulations as part of its Licaps Drug Delivery System.

Sell $2.4B
Mergr

Product

Company

Legal